Curasight
Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company's clinical progress, including the recent initiation of a Phase 1 trial with uTREAT® in aggressive brain cancer, and the ongoing Phase 2 trial of uTRACE® in prostate cancer conducted in partnership with Curium Inc.
About the uPAR theranostic platform
Curasight's uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight's ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers.
| Datum | 2026-01-05, kl 10:30 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!